Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)...

全面介紹

Na minha lista:
書目詳細資料
發表在:Clin Pharmacol Ther
Main Authors: Biemans, Vince B.C., van der Woude, C. Janneke, Dijkstra, Gerard, van der Meulen‐de Jong, Andrea E., Oldenburg, Bas, de Boer, Nanne K., Löwenberg, Mark, Srivastava, Nidhi, Bodelier, Alexander G.L., West, Rachel L., Jansen, Jeroen M., de Vries, Annemarie C., Haans, Jeoffrey J.L., de Jong, Dirk J., Pierik, Marie J., Hoentjen, Frank
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2019
主題:
Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7232860/
https://ncbi.nlm.nih.gov/pubmed/31677154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1712
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍